Trial Profile

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 20 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ETX 19477 (Primary)
Indications Solid tumours
Focus Adverse reactions
Acronyms ERADIC8
Sponsors 858 Therapeutics

Most Recent Events

05 Aug 2025 Planned number of patients changed from 48 to 120.
05 Aug 2025 Planned primary completion date changed from 1 Dec 2025 to 1 Dec 2026.
26 Sep 2024 According to 858 Therapeutics media release, once a recommended dose for expansion is identified, the company will initiate tumor- and biomarker-focused Phase 2 cohorts.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com